Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | KAT7 | O95251 | 1/20 | 0.30 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24276763 | 0.96 | LMNA (0.30) | LMNANPSR1 | |
| SCHEMBL31692233 | 0.83 | NPSR1 (0.35) | LMNANPSR1KAT7KAT8 | |
| SCHEMBL31692539 | 0.80 | KAT7 (0.35) | LMNANPSR1KAT7KAT8 | |
| SCHEMBL24276951 | 0.78 | CSNK1E (0.36) | — | |
| SCHEMBL29308618 | 0.78 | SETD7 (0.31) | — | |
| SCHEMBL24276775 | 0.78 | USP30 (0.33) | LMNANPSR1KAT7KAT8 | |
| SCHEMBL31692340 | 0.78 | GLP1R (0.36) | — | |
| SCHEMBL24276772 | 0.77 | SPR (0.31) | — | |
| SCHEMBL24276764 | 0.76 | MAP4K4 (0.33) | LMNANPSR1KAT7KAT8 | |
| SCHEMBL31692464 | 0.74 | LMNA (0.36) | LMNANPSR1KAT7KAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | BIOMEA FUSION, INC. | 2025-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304572-A1 | HETEROCYCLIC GLP-1R AGONISTS | GLP1R, GPR119, GIPR | LMNA 3557/4885NPSR1 268/4885KAT7 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.